Business Description
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Business History
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 5.48
Total Equity: $2.72B
Shares: 156,000,000
Total Debt: $1.99B
Cash: $1.42B
EBITDA: $1.46B
Total Debt: $1.99B
Cash: $1.42B
Revenue: $4.34B
Revenue: $4.34B
Revenue: $4.34B
Total Equity: $2.72B
Tax Rate: 21.7%
Equity: $2.72B
Total Debt: $1.99B
Cash: $1.42B
Current Liabilities: $1.59B
Long-Term Debt: $1.49B
Total Debt: $1.99B
Total Equity: $2.72B
Shares: 156,000,000
Shares: 156,000,000
CapEx: -$148.00M
Shares: 156,000,000
Stock Price: $176.55
Net Income: $850.00M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 21, 2026 7:32pm (5d ago)| Metric | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.5B | $4.6B | $4.5B | $4.4B | $4.3B |
| Cost of Revenue | $1.4B | $1.6B | $1.8B | $1.5B | $1.4B |
| Gross Profit | $3.2B | $3.0B | $2.7B | $2.9B | $2.9B |
| Operating Expenses | $3.3B | $7.2B | $3.8B | $3.7B | $2.0B |
| Operating Income | -$123.0M | -$4.2B | -$1.1B | -$833.0M | $864.0M |
| Net Income | $762.0M | -$4.4B | -$1.2B | -$1.2B | $850.0M |
| EBITDA | $1.2B | -$3.9B | -$608.0M | -$725.0M | $1.5B |
| EPS | $5.08 | $-28.05 | $-7.35 | $-7.69 | $5.48 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 21, 2026 7:32pm (5d ago)| Metric | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.2B | $2.0B | $1.0B | $1.1B | $1.4B |
| Total Current Assets | $2.7B | $3.6B | $2.6B | $2.7B | $3.3B |
| Total Assets | $15.2B | $12.3B | $10.1B | $6.3B | $6.6B |
| Current Liabilities | $1.1B | $2.8B | $1.6B | $1.5B | $1.6B |
| Long-Term Debt | $1.7B | $1.5B | $1.5B | $1.5B | $1.5B |
| Total Liabilities | $4.5B | $5.7B | $4.4B | $3.9B | $3.9B |
| Total Equity | $10.7B | $6.6B | $5.7B | $2.4B | $2.7B |
| Retained Earnings | $5.5B | $1.1B | -$19.0M | -$1.2B | -$392.0M |
Cash Flow (Annual)
Last updated: Jun 21, 2026 7:32pm (5d ago)| Metric | 2022 | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $545.0M | $392.0M | $478.0M | $837.0M | $1.1B |
| Capital Expenditure | -$208.0M | -$286.0M | -$195.0M | -$128.0M | -$148.0M |
| Free Cash Flow | $337.0M | $106.0M | $282.0M | $709.0M | $931.0M |
| Acquisitions (net) | -$2.4B | -$265.0M | -$29.0M | $2.0M | -$10.0M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | -$116.0M | -$742.0M |
| Net Change in Cash | -$578.0M | $779.0M | -$963.0M | $79.0M | $291.0M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 8:41am (16m ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$4.8B $4.8B – $4.9B
|
$5.2B $5.2B – $5.2B
|
$5.6B $5.5B – $5.6B
|
$5.8B $5.8B – $5.9B
|
| EBITDA |
-$536.3M -$544.1M – -$530.8M
|
-$573.1M -$573.4M – -$572.8M
|
-$616.7M -$624.2M – -$610.1M
|
-$647.1M -$654.9M – -$640.1M
|
| Net Income |
$932.5M $886.7M – $978.4M
|
$1.0B $1.0B – $1.2B
|
$1.2B $1.2B – $1.3B
|
$1.4B $1.4B – $1.4B
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 21, 2026 7:32pm (5d ago)| Metric | 2023 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +1.3% | -1.7% | -2.9% | -0.8% |
| Gross Profit Growth | -5.8% | -7.7% | +4.3% | +1.1% |
| Operating Income Growth | -3,297.6% | +74.4% | +22.1% | +203.7% |
| Net Income Growth | -678.0% | +73.6% | -5.3% | +169.5% |
| EBITDA Growth | -427.4% | +84.5% | -19.2% | +301.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 8:41am (16m ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-25 | Davies Scott M | S-Sale | 615.00 | $180.00 | $110,700 |
| 2026-06-16 | Skovronsky Daniel | A-Award | 1,674.00 | $164.28 | $275,005 |
| 2026-06-16 | Skovronsky Daniel | 0.00 | $0.00 | $0 | |
| 2026-06-05 | Leckman Patricia | S-Sale | 290.00 | $161.79 | $46,919 |
| 2026-06-05 | Leckman Patricia | S-Sale | 374.00 | $162.78 | $60,880 |
| 2026-06-05 | Leckman Patricia | S-Sale | 78.00 | $163.36 | $12,742 |
| 2026-06-05 | Leckman Patricia | S-Sale | 39.00 | $164.82 | $6,428 |
| 2026-06-05 | Leckman Patricia | S-Sale | 2.00 | $167.88 | $336 |
| 2026-06-02 | Leckman Patricia | S-Sale | 176.00 | $160.66 | $28,276 |
| 2026-06-02 | Leckman Patricia | S-Sale | 318.00 | $162.00 | $51,516 |
| 2026-06-02 | Leckman Patricia | S-Sale | 290.00 | $163.02 | $47,276 |
| 2026-05-28 | Meister Keith A. | X-InTheMoney | 24,562.00 | $102.82 | $2.5M |
| 2026-05-28 | Meister Keith A. | J-Other | 24,562.00 | $156.40 | $3.8M |
| 2026-05-28 | Meister Keith A. | S-Sale | 37,590.00 | $156.50 | $5.9M |
| 2026-05-28 | Meister Keith A. | S-Sale | 71,986.00 | $157.38 | $11.3M |
| 2026-05-28 | Meister Keith A. | S-Sale | 110,424.00 | $147.50 | $16.3M |
| 2026-05-29 | Meister Keith A. | S-Sale | 11,760.00 | $159.57 | $1.9M |
| 2026-05-29 | Meister Keith A. | S-Sale | 4,579.00 | $160.50 | $734,930 |
| 2026-05-29 | Meister Keith A. | S-Sale | 5,256.00 | $161.64 | $849,580 |
| 2026-05-29 | Meister Keith A. | S-Sale | 2,225.00 | $162.44 | $361,429 |
Narrative Economics
market-narrative step).